Gain Therapeutics Analyst Price Targets - Benzinga

Gain Therapeutics Inc

GANXNASDAQ

Trade with Public

Trade with Public

$1.95

0.0452.36%

Ult. Agg.: Aug 26, 8:46 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Gain Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gain Therapeutics (GANX).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$8Upside to Avg. PT+287.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 11, 2026	BTIG	Thomas Shrader	Maintained	Buy	$5
Jul 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Jun 30, 2026	BTIG	Thomas Shrader	Maintained	Buy	$5
Dec 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Oct 15, 2025	BTIG	Thomas Shrader	Maintained	Buy	$9
Oct 13, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Oct 7, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$5→$7
Sep 8, 2025	BTIG	Thomas Shrader	Maintained	Buy	$9
Aug 13, 2025	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$7→$6
Jul 3, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
May 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Mar 28, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$6
Mar 17, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Mar 7, 2025	Scotiabank	Louise Chen	Initiate	Sector Outperform	$12
Dec 24, 2024	Roth MKM	Boobalan Pachaiyappan	Maintained	Buy	$7
Dec 5, 2024	Roth MKM	Boobalan Pachaiyappan	Initiate	Buy	$7
Nov 25, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Oct 9, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Oct 1, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Sep 3, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7

Maxim Group analyst Jason McCarthy maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and raises the price target from $5 to $7.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.

Benzinga Newsdesk